Nzimande SP, Govender NP, Maphanga TG. In vitro manogepix susceptibility testing of South African
Emergomyces africanus, Emergomyces pasteurianus, and
Blastomyces emzantsi clinical isolates.
Antimicrob Agents Chemother 2023;
67:e0110423. [PMID:
37971237 PMCID:
PMC10720492 DOI:
10.1128/aac.01104-23]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 10/06/2023] [Indexed: 11/19/2023] Open
Abstract
We performed in vitro antifungal susceptibility testing of manogepix against the yeast phase of 78 Emergomyces africanus, 2 Emergomyces pasteurianus, and 5 Blastomyces emzantsi isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.
Collapse